Enanta Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Fiscal first quarter ended December 31, 2015; unaudited results compared with the three months ended December 31, 2014. Enanta is an R&D-focused biotechnology company whose revenue depends substantially on its AbbVie collaboration and royalties on paritaprevir-containing HCV regimens.
Financial performance and position
| Metric | Q1 FY2016 | Q1 FY2015 |
|---|---|---|
| Revenue | $48.4 million | $77.5 million |
| Operating expenses | $12.9 million | $7.3 million |
| Operating income | $35.6 million | $70.2 million |
| Net income | $26.2 million | $42.0 million |
| Diluted EPS | $1.36 | $2.18 |
| Cash from operating activities | $30.0 million provided | $5.6 million used |
- Revenue comprised $30.0 million in AbbVie milestone payments, $17.9 million in royalties, and $0.6 million under the NIAID contract. The comparable 2014 quarter included a $75.0 million AbbVie milestone, $1.4 million in royalties, and $1.1 million under NIAID.
- Revenue fell 37%; net income fell 38%. Royalties rose substantially, but did not offset the lower milestone revenue. R&D expense doubled to $9.0 million, while G&A increased to $3.8 million.
- Operating margin was approximately 73.5%, versus 90.6% a year earlier. The filing does not report gross profit or gross margin as separate measures.
- At December 31, cash and cash equivalents were $46.2 million; short- and long-term marketable securities totaled $190.4 million. Management reported $236.6 million in cash, cash equivalents and marketable securities, excluding $17.9 million in royalty receivables.
- Total assets were $278.4 million and current liabilities were $10.9 million. The company reported no debt outstanding; it had capital-lease obligations of approximately $0.6 million and a $0.6 million restricted-cash balance supporting a lease letter of credit.
- Operating cash flow improved from use of $5.6 million to provision of $30.0 million. Investing activities used $5.6 million, and financing activities provided $0.1 million. Cash and cash equivalents increased $24.5 million during the quarter.
Business developments, outlook and risks
- AbbVie’s Japan reimbursement approval for a paritaprevir-containing regimen triggered Enanta’s $30 million milestone. Enanta remained eligible for up to $80 million in additional commercialization-approval milestones related to another collaboration protease inhibitor.
- AbbVie reported Phase 2 results for its ABT-493/ABT-530 combination and initiated six Phase 3 trials. AbbVie planned for a first U.S. approval in 2017; development, approval, commercial success and resulting payments remained uncertain.
- Enanta initiated a Phase 1 clinical trial of its wholly owned HCV cyclophilin inhibitor EDP-494 in January 2016. It planned to begin clinical trials of its NASH candidate EDP-305 in calendar 2016. Management expected higher R&D spending as these and other programs advanced.
- Management said existing liquidity should fund anticipated cash requirements for the foreseeable future, while noting that this outlook is subject to uncertainty. Future revenue and profitability are uncertain and depend materially on AbbVie’s development and commercialization, paritaprevir sales and potential milestones.
- Key risks include dependence on AbbVie, intense HCV competition and reimbursement pressure, clinical and regulatory uncertainty, and the costs and execution risks of advancing Enanta’s own pipeline. The filing also notes an October 2015 FDA safety communication concerning VIEKIRA PAK and TECHNIVIE in patients with decompensated cirrhosis.
- A $0.5 million milestone payment under an HCV intellectual-property license was triggered by filing to commence clinical development of the cyclophilin inhibitor. The company reported no pending or threatened litigation and no material change in commitments during the quarter.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- AbbVie’s current and future paritaprevir sales, royalty calculations and product-market allocation, as well as the timing and achievement of any remaining milestones.
- Progress, safety and clinical results for EDP-494 and the timing and costs of EDP-305’s planned clinical entry.
- Whether competition, pricing and reimbursement trends affect AbbVie’s HCV regimens and Enanta’s royalty revenue.
- Actual R&D spending, operating cash flow and liquidity as the company advances its development programs.
- Potential effects of the FDA safety communication and any subsequent regulatory or labeling developments for AbbVie’s marketed regimens.